^
Association details:
| Biomarker: | HR negative + BRCA2 mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) + paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
176P - Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)
Published date:
09/14/2020
Excerpt:
Regardless of the treatment arm, pCR rates were higher in HR- than in HR+ pts (57.9%, 44/76 vs. 41.4%, 12/29;). We observed highest pCR rates in HR- pts with BRCA1/2 mutations (65.8%, 25/38) and lowest in HR+ pts without BRCA1/2 mutations (0%, 0/8).
Trial ID:
